Paroxysmal Nocturnal Hemoglobinuria – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of paroxysmal nocturnal hemoglobinuria (PNH) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of PNH for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s PNH forecast will answer the following questions:
- How will improvements in survival change the number of people living with a diagnosis of PNH?
- Of all people diagnosed with PNH, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PNH over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts eight PNH patient populations, as follows:
- Diagnosed prevalent cases of PNH.
- Diagnosed incident cases of PNH.
- Diagnosed prevalent cases of classical PNH.
- Diagnosed prevalent cases of PNH with bone marrow disorders.
- Diagnosed prevalent cases of PNH with aplastic anemia.
- Diagnosed prevalent cases of PNH with myelodysplastic syndrome.
- Diagnosed cases of subclinical PNH.
- Diagnosed drug-treated prevalent cases of PNH.
Note: Coverage may vary by country.
